LifeNet Health, a leading allograft bio-implant company, announces the first implant of a CardioGraft(TM) allograft cardiac patch product with MatrACELL(TM)( )decellularization technology. The surgery was performed at Children's Mercy Hospital in Kansas City, Mo by Gary K. Lofland, MD, FACS, Section Chief, Cardiovascular Surgery at Children's Mercy Hospital in Kansas City, Mo, The Joseph Boon Gregg/Missouri Endowed Chair in Pediatric Cardiac Surgery, Professor of Surgery, UMKC. The initial preclinical testing in large animal models was coordinated by Richard A. Hopkins, MD, Director, Cardiac Surgery Research Laboratories, Chief, Adolescent/Adult Congenital Cardiac Surgery at Children's Mercy Hospital in Kansas City, Mo, Professor of Surgery, UMKC.
MatrACELL(TM) Technology is a patented and validated process to render allograft tissue acellular, removing over 99% of the donor genetic material. It is well documented in the surgical literature that the donor cell component of cryopreserved cardiovascular tissue is the source of its three primary failure modes: calcification, stenosis and immunogenicity. MatrACELL(TM) Technology is a methodology that safely removes donor cells from cardiovascular tissues while retaining the native biomechanical strength of the tissue.